Nitroprusside treatment of erythromelalgia in an adolescent female.
OBJECTIVE
To report a case of erythromelalgia in an adolescent patient successfully treated with nitroprusside.


METHODS
A 15-year-old girl with erythromelalgia resistant to aspirin therapy received an infusion of nitroprusside. The response of the erythromelalgia to nitroprusside was dramatic, with complete pain resolution within 17 hours after the start of therapy. No relapse of erythromelalgia was seen when nitroprusside was discontinued and the patient remained well after 6 months.


CONCLUSIONS
This case adds to existing literature substantiating the benefit of nitroprusside for the treatment of erythromelalgia in pediatric patients. Erythromelalgia in children may represent a different disease entity than that seen in adults, which is commonly responsive to aspirin therapy. The pathogenesis of erythromelalgia is unclear and precludes formulating a proposed mechanism by which nitroprusside has benefit in children.


CONCLUSIONS
Nitroprusside is valuable for erythromelalgia resistant to aspirin therapy in pediatric patients. Because of unanswered questions regarding the disease, aspirin remains the agent of first choice in all patients with this rare disease.
Stone
J D
JD
Community Medical Center, Missoula, MT, USA.
Rivey
M P
MP
Allington
D R
DR
D000293:Adolescent; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004916:Erythromelalgia / Q000188:drug therapy* / Q000534:rehabilitation; D005260:Female; D006801:Humans; D009599:Nitroprusside / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D018712:Analgesics, Non-Narcotic; D014665:Vasodilator Agents; D009599:Nitroprusside; D001241:Aspirin